A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy

Author： Shin Sang  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 672-680

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

By Shin Sang   Jeung Hei-Cheul   Ahn Joong   Rha Sun   Roh Jae   Park Kyung   Kim Dal-Hyun   Kim Chin   Chung Hyun  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 650-658

Springer Publishing Company

Access to resources Recommend Favorite

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

By Gartner Elaina   Griffith Kent   Pan Quintin   Brewer George   Henja Gwen   Merajver Sofia   Zalupski Mark  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 159-165

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

By Shitara Kohei  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 787-793

Springer Publishing Company

Access to resources Recommend Favorite

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1501-1510

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

By Strickler John   McCall Shannon   Nixon Andrew   Brady John   Pang Herbert   Rushing Christel   Cohn Allen   Starodub Alexander   Arrowood Christy   Haley Sherri   Meadows Kellen   Morse Michael   Uronis Hope   Blobe Gerard   Hsu S.   Zafar S.   Hurwitz Herbert  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 330-339

Springer Publishing Company

Access to resources Recommend Favorite